Source link : https://www.newshealth.biz/health-news/teprotumumab-improves-thyroid-eye-disease-across-phenotypes/
NEW ORLEANS — Comparable improvements were observed with teprotumumab (Tepezza) between patients with age-related phenotypic I or II thyroid eye disease, according to results from a post-hoc analysis. At 24 weeks, 81% of patients with phenotypic I thyroid eye disease (those younger than 40 years) and 73.7% of those with phenotypic II disease (those 40 […]
Author : News Health
Publish date : 2024-05-10 16:47:11
Copyright for syndicated content belongs to the linked Source.
in Health